Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-05-31
2011-05-31
Yu, Misook (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500
Reexamination Certificate
active
07951924
ABSTRACT:
In one aspect, the present invention concerns RhoB variant polypeptides and isolated degenerate polynucleotides encoding the RhoB variant polypeptides. In another aspect, the present invention concerns nucleic acid constructs containing a polynucleotide encoding a RhoB variant polypeptide, and host cells genetically modified to express such polynucleotides. In another aspect, the present invention provides a method of inhibiting the growth of, and inducing apoptosis in, cancerous cells by contacting the cells with an effective amount of a RhoB variant.
REFERENCES:
patent: 7144711 (2006-12-01), Cismowski et al.
patent: 2002/0034725 (2002-03-01), McKenna et al.
patent: 2003/0018003 (2003-01-01), Sebti
patent: 2004/0171547 (2004-09-01), Sebti
patent: 2006/0137042 (2006-06-01), Plesch et al.
patent: WO 01/97828 (2001-12-01), None
Adamson et al., J Biol Chem, 1992, 267:20033-20038.
Adamson, P. et al. “Post-translational modifications of p21rhoproteins”J Biol Chem, 1992, 267:20033-20038.
Adjei, A.A. “Ras signaling pathway proteins as therapeutic targets”Curr Pharm Design, 2001, 7:1581-1594.
Adnane, J. et al. “Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients”Clin Cancer Res, 2002, 8:2225-2232.
Adnane, J. et al. “RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1”J Biol Chem, 2002, 277:8500-8507.
Alimandi, M. et al. “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas”Oncogene, 1995, 10:1813-1821.
Arboleda, M.J. et al. “Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells”Cancer Res, 2003, 63:196-206.
Armstrong, S.A. et al. “CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB”J Biol Chem, 1995, 270:7864-7868.
Barbacid, M. “rasGenes”Annu. Rev. Biochem., 1987, 56:779-827.
Baron, R. et al. “RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: Evidenced in vivo by an anti-farnesyl cysteine antibody”Proc Natl Acad Sci USA, 2000, 97:11626-11631.
Bos, J.L. “rasoncogenes in human cancer: A review”Cancer Res., 1989, 49:4682-4689.
Buday, L. and Downward, J. “Epidermal growth factor regulates p21rasthrough the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor”Cell, 1993, 73:611-620.
Campbell, S.L. et al. “Increasing complexity of Ras signaling”Oncogene, 1998, 17:1395-1413.
Caponigro, F. “Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?”Anti-Cancer Drugs, 2002, 13:891-897.
Chang, F. et al. “Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention”Leukemia, 2003, 17:1263-1293.
Chardin, P. et al. “Coding sequence of humanrhocDNAs clone 6 and clone 9”Nucleic Acids Res. 1988, 16: 2717.
Chen, Z. et al. “Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice”J Biol Chem, 2000, 275(24):17974-17978.
Chen, Z. et al. “Farnesylated and geranylgeranylated RhoB suppress the transformation of PANC-1 human pancreatic cancer cells” Proceedings of the 91stAnnual Meeting of the American Association of Cancer Research, vol. 14, p. 220, abstract No. 1402, 2000.
Clark, E.A. et al. “Genomic analysis of metastasis reveals an essential role for RhoC”Nature, 2000, 406:532-535.
Cox, A.D. et al. “Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?”Biochim. Biophys. Acta., 1997, 1333:F51-F71.
Davies, M.A. et al. “Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells”Clin Cancer Res, 2002, 8:1904-1914.
Downward, J. “Targeting Ras signaling pathways in cancer therapy”Nat Rev Cancer, 2003, 3:11-22.
Du, W. et al. “Cell growth inhibition by farnesyltransferase inhibitors in mediated by gain of geranylgeranylated RhoB”Mol Cell Biol, 1999, 19(3):1831-1840.
Du, W. and Prendergast, G.C. “Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors”Cancer Res, 1999, 59:5492-5496.
End, D.W. et al. “Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro”Cancer Res., 2001, 61:131-137.
Forget, M.A. et al. “The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers”Clin Exp Metastasis, 2002, 19(1):9-15.
Fritz, G. et al. “The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments”J Biol Chem, 1995, 270(42):25172-25177.
Fritz, G. and Kaina, B. “rhoBencoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase”J Biol Chem, 1997, 272(49):30637-30644.
Fritz, G. and Kaina, B. “Ras-related GTPase RhoB represses NF-κB signaling”J Biol Chem, 2001, 276:3115-3122.
Fukata, M. et al. “Roles of Rho-family GTPases in cell polarisation and directional migration”Curr Opin Cell Biol, 2003, 15:590-597.
GENBANK accession No. X06820, “H. sapiensrhoB gene mRNA” Oct. 24, 1996.
GENBANK accession No. CAA29968, “rhoB [Homo sapiens]” Oct. 24, 1996.
Gibbs, J.B. et al. “The potential of farnesyltransferase inhibitors as cancer chemotherapeutics”Annu. Rev. Pharmacol. Toxicol., 1997, 37:143-166.
Gura, T. “Systems for identifying new drugs are often faulty”Science, 1997, 278:1041-1042.
Hall, A. “Rho GTPases and the actin cytoskeleton”Science, 1998, 279(5350):509-514.
Hunter, T. “Oncoprotein networks”Cell, 1997, 88:333-346.
Jahner, D. and Hunter, T. “Theras-related generho Bis an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts”Mol Cell Biol, 1991, 11(7):3682-3690.
Jiang, K. et al. “Regulation of Akt-dependent cell survival by Syk and Rac”Blood, 2003, 101:236-244.
Jiang, K. et al. “Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis”Mol Cell Biol, 2004, 24:5565-5576.
Jiang, K. et al. “EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation”Oncogene, 2004, 23:1136-1145.
Kerbel, R.S. “Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans”Cancer Biol.&Ther., 2003, 2(4 Supp. 1):S134-S139.
Khosravi-Far, R. and Der, C.J. “The Ras signal transduction pathway”Cancer Metastasis Rev, 1994, 13:67-89.
Khosravi-Far, R. et al. “Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation”Mol Cell Biol, 1995, 15(11):6443-6453.
Kim, D. et al. “Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production”Faseb J, 2001, 15:1953-1962.
Kubiatowski, T. et al. “Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas”J Neurosurg, 2001, 95:480-488.
Lebowitz, P.F. et al. “Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity”Mol Cell Biol, 1995, 15(12):6613-6622.
Lebowitz et al. “Farnesyltransferase inhibitors alter the prenylations and growth-stimulating
Halvorson Mark
Saliwanchik Lloyd & Eisenschenk
University of South Florida
Yu Misook
LandOfFree
RhoB variants and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RhoB variants and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RhoB variants and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687695